The integration of Oracle Argus enables QPS to better capture, manage, and report adverse events for regulatory requirements.

In this GEN webinar, experts from Perceptive Imaging and Flywheel explore how imaging data access issues slow decision-making and increase risks for both biopharma and CROs.

Dec 24 (Reuters) - Biohaven (BHVN.N), opens new tab said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication yet. Retatrutide is a triple-agonist ...

Tailoring breast cancer screening to a woman's individual cancer risk might work better than annual mammograms, a new study says. Women had breast cancers caught at an earlier, more treatable stage ...

Mass General Brigham has announced the development of an AI company and screening tool that has sped up the process for determining a patient’s eligibility and enrollment for clinical trials.

EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune ...

When Chase Johnson was 31, her dog began acting strange. He was anxious, wouldn’t leave her side and, one day, pushed his nose into the side of her breast. Johnson felt a hard lump. “I wasn’t someone ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — The Food and Drug ...

The FDA has authorized a Phase 3 trial of PrimeC, an experimental oral therapy for ALS. In a prior Phase 2b study, PrimeC slowed ALS progression by 37.4% and improved survival by 43% in key patient ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression Endocrinologist Daniel ...